According to drug and device manufacturers, the US government shutdown which began on October 1, 2013 isn’t preventing the Food and Drug.
According to drug and device manufacturers, the US government shutdown which began on October 1, 2013 isn’t preventing the Food and Drug Administration from having their scheduled advisory committee meetings this month.
As with several other government sponsored organizations, analysts believed that the shutdown would severely impact FDA’s panel discussions, postpone meetings and ultimately delay various anticipated product launches.
Approximately half of the FDA’s staff has been retained during the shutdown and the majority of those staffers have responsibilities that only utilize funds resulting from user fees paid by drug and device companies in exchange for performance goals. In contrast, the FDA noted that the government’s shutdown has impacted food safety, nutrition and cosmetics initiatives.
“Since the underlying activities and staff are paid for by a combination of user fees and appropriated funds, it is too early to predict the priorities and achievable workload of the retained staff,” the Alliance for a Stronger FDA, a group that advocates for FDA resources, said in a statement last week.
In October, there are nine advisory committee meetings scheduled.
Next week, the Encdocrinologic and Metabolic Drugs Advisory Committee will discuss the supplemental new drug application, NDA 202057/S-005, Vascepa (icosapent ethyl) Capsules, submitted by Amarin Pharmaceuticals Ireland Ltd. View the meeting announcement HERE!
ISS has over a decade of experience in developing regulatory strategies including support for FDA Advisory Committee meetings. We are involved in more FDA AdComms per year than even the largest pharmaceutical companies. For more information on how ISS can help you prepare for your next meeting, contact firstname.lastname@example.org.
Over the past few years, the number of ex-US manufacturers submitting a Class II exempt 510k device registration has increased substantially. For companies with medical devices that are approved and successful in a foreign market, the logical next step is to introduce their product into the US, which has one of the most lucrative healthcare markets in the world. Read more
FDA advisory committee meetings are important regulatory events for many manufacturers on the path to marketing approval. These meetings can quite literally result in the approval or rejection of a product based on the panel’s vote. Read more
One of the main challenges our clients face is determining which regulatory pathway is best for their products. For example, what if an OTC product has a Monograph active ingredient but that ingredient is present at a different amount than the permitted amount? Or what if the label claims a novel indication not specified in a Monograph? If you are debating pursuit of either regulatory pathway for your OTC drug, it is critical to consider cost, timeline, and label claims to ensure your products has a unique stance in today’s market. Read more
US distributors and agents trying to import rapid antibody tests for coronavirus face a number of obstacles. The good news is that FDA has opened up the Emergency Use Authorization (EUA) program to include SARS-CoV-2 (the virus) and COVID-19 (the disease), expediting time to market. Read more
The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us todayContact us